Day One Biopharmaceuticals
395 Oyster Point Blvd., Suite 217
South San Francisco
About Day One Biopharmaceuticals
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.
14 articles with Day One Biopharmaceuticals
Day One Receives FDA Rare Pediatric Disease Designation for DAY101 for the Treatment of Pediatric Low-Grade Glioma
Day One Biopharmaceuticals announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to the Company’s lead product candidate, DAY101, for the treatment of low-grade gliomas harboring an activating RAF alteration that disproportionately affects children.
Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, announced that the European Commission has granted orphan designation for the Company’s lead product candidate, DAY101, for the treatment of glioma.
There were seven initial public offerings (IPOs) for biotech companies in the month of May. Here’s a look.
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $16.00 per share
5/12/2021Catch up on the investment news quickly with BioSpace's brief overview of the biotech companies hitting the Nasdaq and raking in fresh cash the past week.
Day One Announces First Patient Dosed in FIREFLY-1 Pivotal Phase 2 Clinical Trial of DAY101 in Pediatric Progressive Low-Grade Glioma
FIREFLY-1 is designed to support regulatory registration of DAY101 in pediatric low-grade glioma (pLGG), which is the most common form of childhood brain cancer and has no approved therapies DAY101 is an oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor with demonstrated evidence of anti-tumor activity in pLGG
With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life science companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the appointment of Ms. Saira Ramasastry to the Company’s board of directors.
Day One Expands Clinical-Stage Oncology Pipeline; Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize MEK Inhibitor Pimasertib
Exclusive license agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of pimasertib and MSC2015103B Day One plans to evaluate the combination of pimasertib and DAY101, the Company’s clinical-stage pan-RAF kinase inhibitor, in patients ≥12 years of age with advanced solid tumors
Day One Appoints Charles N. York II as Chief Operating and Financial Officer and Expands Board of Directors with the Addition of Natalie Holles
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies for children and adults with cancer, today announced the appointment of Charles N. York II as chief operating and financial officer and the addition of Natalie Holles to the Company’s board of directors.
Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies for children and adults with cancer, today announced a $130 million Series B financing from leading life sciences investors
Day One Announces Preliminary Phase 1 Results for DAY101 in Pediatric Low-Grade Glioma, Receipt of Breakthrough Therapy Designation (BTD) and New Phase 2 Study
Day One Biopharmaceuticals, a company driven to develop promising new oncology therapies for both children and adults living with cancer, announced interim results from PNOC014, an ongoing Phase 1 investigator-sponsored study conducted by Dana-Farber and the Pacific Pediatric Neuro-Oncology Consortium (PNOC) of DAY101 in children with radiographically recurrent/progressive low-grade gliomas and other MAP kinase pathway activated tumors.
Day One Announces Expansion of Executive Leadership Team and Board of Directors, including Jeremy Bender, Lisa Bowers, and John Josey
Day One announces today the expansion of its executive team and Board of Directors.
Day One Biopharmaceuticals shares plans to rapidly develop new cancer treatments for people of all ages and announces $60M Series A funding and lead clinical-stage program acquired through Takeda
Day One Biopharmaceuticals, LLC. Using new insights from the biology of pediatric cancer, Day One Biopharmaceuticals develops promising new oncology therapies that change outcomes for people of all ages. Today, Day One unveils its team, $60M Series A financing, and announces its first promising clinical-stage oncology treatment, which Day One acquired through Takeda Pharmaceutical Company Limited.